Profile data is unavailable for this security.
About the company
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
- Revenue in USD (TTM)33.88m
- Net income in USD-26.96m
- Incorporated2023
- Employees176.00
- LocationCASI Pharmaceuticals Inc9620 Medical Center Drive, Suite 300BEIJING 100025ChinaCHN
- Phone+86 1 065618789
- Fax+1 3 013152437
- Websitehttp://www.casipharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LianBio - ADR | 0.00 | -87.98m | 33.94m | 163.00 | -- | 0.1664 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 34.60m | 61.00 | -- | 3.66 | -- | 28.46 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| Fortress Biotech Inc | 84.51m | -68.67m | 34.62m | 186.00 | -- | 1.21 | -- | 0.4097 | -8.88 | -8.88 | 10.29 | 1.49 | 0.366 | 2.19 | 3.89 | 454,371.00 | -66.76 | -52.50 | -117.74 | -99.46 | 68.45 | 63.17 | -182.40 | -236.94 | 1.26 | -11.31 | 0.9758 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Vyne Therapeutics Inc | 424.00k | -27.87m | 35.25m | 10.00 | -- | 0.3972 | -- | 83.13 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Nuo Therapeutics Inc | 608.53k | -3.17m | 35.39m | -- | -- | 34.06 | -- | 58.16 | -0.0754 | -0.0754 | 0.0145 | 0.0235 | 0.2471 | 0.5609 | 3.55 | -- | -128.78 | -116.16 | -173.76 | -354.84 | 79.28 | 70.02 | -521.17 | -854.53 | 2.01 | -1,002.61 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 33.88m | -26.96m | 35.92m | 176.00 | -- | 1.48 | -- | 1.06 | -2.02 | -2.02 | 2.54 | 1.81 | 0.3951 | 1.26 | 3.01 | 192,494.30 | -30.57 | -34.75 | -45.42 | -46.91 | 59.19 | 55.98 | -77.37 | -153.72 | 2.60 | -- | 0.4388 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Apollomics Inc | 0.00 | -677.48k | 36.69m | -- | -- | 0.0438 | -- | -- | -0.0505 | -0.0505 | 0.00 | 9.36 | 0.00 | -- | -- | -- | -0.6357 | -- | -0.6538 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -281.92 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 36.80m | 1.00 | -- | 0.2055 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| China Health Industries Holdings, Inc. | 117.28k | -1.51m | 36.93m | 32.00 | -- | -- | -- | 314.90 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 37.09m | 57.00 | -- | 0.6472 | -- | 16.56 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Rapid Micro Biosystems Inc | 22.52m | -52.47m | 37.11m | 193.00 | -- | 0.3558 | -- | 1.65 | -1.22 | -1.22 | 0.5234 | 2.78 | 0.1348 | 1.36 | 4.07 | 116,678.80 | -31.41 | -- | -35.44 | -- | -24.36 | -- | -232.99 | -- | 5.29 | -- | 0.0026 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| OncoCyte Corp | 1.50m | -25.80m | 37.15m | 43.00 | -- | 1.12 | -- | 24.71 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Marker Therapeutics Inc | 3.31m | -14.05m | 37.39m | 8.00 | -- | 2.66 | -- | 11.29 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Promis Neurosciences Inc | 0.00 | -13.21m | 37.64m | 6.00 | -- | 9.99 | -- | -- | -1.22 | -1.22 | 0.00 | 0.1987 | 0.00 | -- | -- | 0.00 | -128.63 | -144.28 | -552.70 | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to CASI Pharmaceuticals Inc's reporting currency: US Dollar USD
2.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Shields Capital Management LLCas of 31 Dec 2023 | 133.15k | 1.00% |
| Wellington Shields & Co. LLC (Investment Management)as of 31 Dec 2023 | 44.29k | 0.33% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 29.10k | 0.22% |
| Geode Capital Management LLCas of 31 Dec 2023 | 22.22k | 0.17% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 19.74k | 0.15% |
| Citadel Securities LLCas of 31 Dec 2023 | 12.92k | 0.10% |
| Jane Street Capital LLCas of 31 Dec 2023 | 12.54k | 0.09% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.38k | 0.01% |
| UBS Securities LLCas of 31 Dec 2023 | 1.22k | 0.01% |
| Simplex Trading LLCas of 31 Mar 2024 | 623.00 | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
